Related Experiment Video

Updated: Jun 15, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Electrocardiographic effects of dexmedetomidine in patients with congenital heart disease

Constantinos Chrysostomou1, Rukmini Komarlu, Steven Lichtenstein

  • 1Department of Pediatric Cardiology, Division of Cardiac Intensive Care, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15201, USA. chrycx@chp.edu

Intensive Care Medicine
|March 10, 2010
PubMed

Insights

Dexmedetomidine use in pediatric patients with congenital heart disease or after heart surgery showed no significant electrocardiogram (ECG) abnormalities. Heart rate decreased, but other ECG intervals remained stable, indicating safety.

Area of Science:

  • Pediatric Cardiology
  • Anesthesiology
  • Clinical Electrophysiology

Background:

  • Dexmedetomidine is commonly used for sedation and analgesia in pediatric patients.
  • Its effects on electrocardiographic (ECG) parameters in children with congenital heart disease (CHD) or post-cardiothoracic surgery require thorough assessment.
  • Understanding these effects is crucial for safe clinical practice.

Purpose of the Study:

  • To evaluate the electrocardiographic (ECG) effects of dexmedetomidine in pediatric patients undergoing procedures related to congenital heart disease (CHD) or cardiothoracic surgery.
  • To compare ECG changes in patients receiving dexmedetomidine with a control group not receiving the drug.

Main Methods:

  • A prospective observational study was conducted on pediatric patients aged 0-17 years with CHD or post-cardiothoracic surgery.
  • Two ECGs were recorded: one at baseline (T1) and one during dexmedetomidine infusion (T2).
  • A control group of patients not receiving dexmedetomidine was included for comparison.

Main Results:

  • In the dexmedetomidine group, heart rate (HR) significantly decreased (P < 0.001).
  • PR interval (P = 0.01) and QRS duration (P = 0.02) showed statistically significant decreases, while QTc remained unchanged.
  • No significant differences in ECG intervals were observed compared to the control group, except for a trend towards lower HR (P = 0.08). Neonates and infants experienced a more pronounced HR drop.
  • No atrioventricular block or arrhythmias were noted in the dexmedetomidine group.

Conclusions:

  • Dexmedetomidine administration in pediatric patients with CHD or following cardiothoracic surgery is not associated with significant ECG interval abnormalities.
  • A trend towards lower heart rate is observed, particularly in younger infants.
  • The study supports the safety of dexmedetomidine regarding ECG parameters in this vulnerable population.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...